Kintara Therapeutics Quote - KTRA

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Current Price

0.257

Bid

0.22

Offer

0.35

Volume

38,292,269

0.24 Day's Range 0.3368

0.081 52 Week Range 5.60

Market Cap

13.826M

Previous Close

0.2749

Open

0.3085

Last Trade

350

0.257

(formt)

Last Trade Time

Financial Volume

US$ 10,809,490

VWAP

0.282289

Average Volume (3m)

15,746,366

Shares Outstanding

55,304,613

Dividend Yield

PE Ratio

-0.92

Earnings Per Share (EPS)

-0.27

Revenue

Net Profit

-15.02M

Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and ... Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC. VAL-083 is a small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including the central nervous system, ovarian, and other solid tumors. The company is also advancing its proprietary late stage photodynamic therapy (PDT) platform that holds promise as a localized cutaneous or visceral tumor treatment as well as in other potential indications. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.kintara.com

Headquarters

Reno, Nevada, USA

Founded

1970

Kintara Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker KTRA. The last closing price for Kintara Therapeutics was US$0.27. Over the last year, Kintara Therapeutics shares have traded in a share price range of US$ 0.081 to US$ 5.60.

Kintara Therapeutics currently has 55,304,613 shares in issue. The market capitalisation of Kintara Therapeutics is US$13.83 million. Kintara Therapeutics has a price to earnings ratio (PE ratio) of -0.92.

TuHURA Biosciences and Kintara Therapeutics Announce Positive Results from Phase 1b Trial of IFx-2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC)

TuHURA Biosciences and Kintara Therapeutics Announce Positive Results from Phase 1b Trial of IFx-2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell...

Period †	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0.062	31.7948717949	0.195	0.3368	0.1703	18648830	0.24929684	CS
4	0.089	52.9761904762	0.168	0.417	0.1508	19667732	0.26515818	CS
12	0.159	162.244897959	0.098	0.417	0.0925	15746366	0.19861246	CS
26	0.0771	42.8571428571	0.1799	0.417	0.081	14074181	0.16395868	CS
52	-3.043	-92.2121212121	3.3	5.6	0.081	7209785	0.19326602	CS
156	-97.743	-99.737755102	98	142.5	0.081	3396098	6.79106375	CS
260	-60.243	-99.5752066116	60.5	167.5	0.081	2814918	11.85127039	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
ME1OEMelodiol Global Health Ltd	AUD 0.006 (100.00%)	34
K2FK2fly Limited	AUD 0.1825 (82.50%)	2.49M
PRXProdigy Gold NL	AUD 0.003 (50.00%)	100.11k
ARVOCArtemis Resources Limited	AUD 0.003 (50.00%)	1.05M
MTBMount Burgess Mining Nl	AUD 0.0015 (50.00%)	5.38k
BNROBulletin Resources Limited	AUD 0.001 (-66.67%)	100k
FRSOAForrestania Resources Ltd	AUD 0.006 (-57.14%)	26k
GGEOAGrand Gulf Energy Limited	AUD 0.001 (-50.00%)	2.18M
D2OOADuxton Water Limited	AUD 0.021 (-47.50%)	4.5k
CT1Constellation Technologies Limited	AUD 0.002 (-33.33%)	50.02k
REDRed 5 Limited	AUD 0.4175 (3.09%)	135.31M
BGLBellevue Gold Limited	AUD 1.835 (-1.34%)	81.32M
NICNickel Industries Ltd	AUD 0.825 (-3.23%)	62.62M
S32South32 Limited	AUD 3.74 (1.77%)	56.22M
CXOCore Lithium Ltd	AUD 0.0855 (-6.04%)	56.06M